<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401620</url>
  </required_header>
  <id_info>
    <org_study_id>FUN-TOC-2014-01</org_study_id>
    <nct_id>NCT02401620</nct_id>
  </id_info>
  <brief_title>Validation of a Tolerability Questionnaire in Rheumatoid Arthritis</brief_title>
  <official_title>Validation of a Specific Questionnaire to Assess the Tolerability of the Different Therapeutic Strategies in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to assess the measurement properties of a tolerability
      questionnaire. The results obtained in patients with Rheumatoid Arthritis (RA) being treated
      will be robust and will assess the patient's tolerability to the treatment. Patients with
      greater tolerability will be more satisfied with their treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinicians do not have any standardized questionnaire to assess the tolerability from the
      patient's perspective. The tolerability assessment of the different pharmacological
      strategies for Rheumatoid Arthritis, from the patient's perspective, would provide additional
      information, improve doctor-patient communication and improve both adherence to and efficacy
      of treatment. For these reasons, the development and validation of a new tool is necessary
      not only for future researches, but for use in standard clinical practice.

      The first phase of the development of the questionnaire has already been completed. The
      second phase of the development of the questionnaire has been designed at to validate the
      tool in the Spanish population.

      This study aims to assess the measurement properties of a new tool which assesses the impact
      of daily life in Rheumatoid Arthritis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of a new questionnaire to measure the tolerability to the pharmacological treatment in RA patients in patient's perspective.</measure>
    <time_frame>10 months</time_frame>
    <description>To validate (evaluate measurement properties) a new questionnaire to measure the tolerability to the pharmacological treatment in RA patients in routine clinical practice</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the feasibility of the questionnaire by non-response rate and the time required to complete it</measure>
    <time_frame>10 months</time_frame>
    <description>To assess the feasibility of the questionnaire by non-response rate and the time required to complete it</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the construct validity of the questionnaire analyzing the relation between questionnaire scores and clinical data (discriminant validity).</measure>
    <time_frame>10 months</time_frame>
    <description>To assess the construct validity of the questionnaire analyzing the relation between questionnaire scores and clinical data (discriminant validity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the reliability of the questionnaire in terms of internal consistency</measure>
    <time_frame>10 months</time_frame>
    <description>To assess the reliability of the questionnaire in terms of internal consistency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>describe socio-demographic and clinical features of the patients recruited in the study.</measure>
    <time_frame>10 months</time_frame>
    <description>To describe socio-demographic and clinical features of the patients recruited in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the adverse reactions (AR) reported by patients impact in the daily life.</measure>
    <time_frame>10 months</time_frame>
    <description>To assess the adverse reactions (AR) reported by patients impact in the daily life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between the tolerability questionnaire and the patient satisfaction</measure>
    <time_frame>10 months</time_frame>
    <description>To assess the correlation between the tolerability questionnaire and the patient satisfaction (ARTS questionnaire)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>single-group studies</arm_group_label>
    <description>Patients with RA diagnosed</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Rheumatoid Arthritis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients over 18 years old.

          2. Patients with RA diagnosed according to the standards of the ACR (American College of
             Rheumatology) in 1987 or to the ACR/EULAR in 2010

          3. Patients on treatment with any Rheumatoid Arthritis drug for at least 3 months before
             their inclusion in the study *

          4. Patients who have provided informed consent prior to taking part in the study.

               -  It's not necessary for patients to be treated in first-line at the moment of the
                  inclusion in the study.

        Exclusion Criteria:

          1. Patients with rheumatic disease other than Rheumatoid Arthritis. Will be exclude
             patients with the following concomitant diseases: Rheumatic autoimmune disease other
             than RA; Functional Class IV as defined by the ACR Classification of Functional Status
             in Rheumatoid Arthritis; Diagnosis of juvenile idiopathic arthritis; inflammatory
             joint disease other than Rheumatoid Arthritis.

          2. Patients with any other concomitant disease or treatment that, under clinical
             criteria, could affect the results of the study or any major episode of infection or
             disease requiring hospitalization.

          3. Patients with any other medical or physiological condition that, in the view of the
             investigator, could compromise the ability of the patient to answer the study
             questions.

          4. Patients who participated in interviews of the Phase I (development of the
             questionnaire)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoni Gomez Centeno</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Corporacio Parc Tauli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoni Gomez Centeno, MD</last_name>
    <phone>0034937496300</phone>
    <phone_ext>6371</phone_ext>
    <email>msarmiento@es.imshealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica Sarmiento</last_name>
    <phone>0034937496300</phone>
    <phone_ext>6371</phone_ext>
    <email>msarmiento@es.imshealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Moisés Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Coromines</last_name>
    </contact>
    <investigator>
      <last_name>Hector Coromines</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raimón Sanmartí</last_name>
    </contact>
    <investigator>
      <last_name>Raimón Sanmartí</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Can Misses</name>
      <address>
        <city>Ibiza</city>
        <zip>07800</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Urruticoechea</last_name>
    </contact>
    <investigator>
      <last_name>Ana Urruticoechea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lluis Espadaler</last_name>
    </contact>
    <investigator>
      <last_name>Lluis Espadaler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Ros</last_name>
    </contact>
    <investigator>
      <last_name>Inmaculada Ros</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni Gomez Centeno</last_name>
    </contact>
    <investigator>
      <last_name>Antoni Gomez Centeno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Antonio D Gómez-Centeno</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>AR: arthritis rheumatoid</keyword>
  <keyword>DMARDs: Disease-modifying antirheumatic drugs</keyword>
  <keyword>ACR. American College of Rheumatology</keyword>
  <keyword>EULAR: European League against rheumatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

